ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source ...

ImmunityBio (IBRX) is jumping 20% after the drug maker reported that the FDA had approved its use of an “alternative source of BCG.” Specifically, the company will now be able to provide this ...

We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going to ...

ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company working to develop therapies that enhance the immune system of patients, instead of weakening it. Since its inception in 2014 ...

Shares of IBRX opened at $3.62 on Friday. ImmunityBio has a one year low of $2.28 and a one year high of $10.53. The firm has a market capitalization of $2.52 billion, a P/E ratio of -3.93 and a ...

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...

Detailed price information for Immunitybio Inc (IBRX-Q) from The Globe and Mail including charting and trades.